MOLLICool

Physiologically optimal mobile cooling therapy

The MOLLICool project aims to develop a portable, mobile cooling therapy system and its commercial implementation by an NMI spin-off (in preparation). A novel, patent-protected technology will combine physiologically optimal cooling for pain relief and decongestion in human and veterinary medicine with outstanding application comfort. Diverse fields of application and corresponding business models are offered in cooling therapy after trauma or surgery (musculoskeletal, dental, cosmetic surgery) as well as for alleviating the side effects of chemotherapy and migraine complaints.

Description

Cooling therapy is used to relieve pain and reduce swelling in musculoskeletal injuries after stress, accidents and operations, as well as to reduce tissue damage and hair loss resulting from chemotherapeutic treatment. It is widely used not only in human medicine, but also in veterinary medicine in the treatment of equine hocks.

Despite the high demand and wide application, the available state of the art has significant shortcomings and leaves important user needs unmet. Freezing pads, while inexpensive, carry the risk of hypothermia, lymphatic congestion, and even tissue damage and require a freezing infrastructure. Currently available devices with temperature control are large and heavy and therefore can only be used in a stationary position, immobilizing the user.

In the MOLLICool project, funded by the EXIST research transfer program of the BMWi and the ESF, a therapy system is being developed that consists of a portable cooling device and a cooling bandage that can be adapted to different body regions and inserted into the device by the user. The system will allow safe application and rapid delivery of cooling effect at physiologically optimal temperature to provide decongestion and pain relief.

The MOLLICool project aims to establish a company from the NMI. Together with interested investors and industrial partners, the medical product is to be approved and marketed. The novel offering of physiologically optimal, mobile cooling therapy will help to bring future practice in cooling therapy to the level desired by physicians and patients.

Period:
01.09.2019 - 31.08.2021
FKZ:
03EFNBW197
Funding:
BMWk